WHO Endorses GLP-One Drugs for Obesity Treatment

The World Health Organization endorses GLP-One drugs for long-term obesity management, recognizing obesity as a chronic disease. These medications, which mimic a natural hormone to reduce appetite, have shown promise in weight loss and lowering risks of conditions like high blood pressure. The WHO emphasizes the need for comprehensive care, including nutritional counseling and physical activity, and calls for lower prices to ensure global accessibility. The Daily News Now! - Every city. Every story. AI Powered. Hosted on Acast. See acast.com/privacy for more information.